VPS53 Suppresses Malignant Properties in Colorectal Cancer by Inducing the Autophagy Signaling Pathway

This article was published in the following Dove Press journal:
OncoTargets and Therapy

Hong Peng¹
Jie Zheng²
Qiang Su³
Xueya Feng¹
Mingsha Peng¹
Lei Gong⁴
Hong Wu¹
Xue Pan⁵

¹Department of Anorectal Surgery, Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College, Nanchong, Sichuan, 637000, People's Republic of China; ²Department of Anesthesiology, Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan 646000, People's Republic of China; ³Department of Pharmacy, Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College, Nanchong Key Laboratory of Individualized Drug Therapy, Nanchong, Sichuan, 637000, People's Republic of China; ⁴Department of Gastrointestinal Surgery, Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College, Nanchong, Sichuan, 637000, People's Republic of China; ⁵Scientific Research Department, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, People's Republic of China

Correspondence: Xue Pan
Scientific Research Department, The First Affiliated Hospital of Chongqing Medical University, No. 1 of Youyi Road, Yuanjiagang, Yuzhong District, Chongqing 400016, People's Republic of China
Tel +86 13594002025
Email panxue89012705@163.com

Background: Many studies found that VPS53, one of the subunits of the golgi-associated retrograde protein (GARP) complexes, was aberrantly expressed in human diseases.

Aim: This study investigated the functions and molecular mechanisms of VPS53 in colorectal cancer (CRC).

Methods: Expression and correlation of Beclin 1 and VPS53 were analyzed by RT-qPCR and Pearson's correlation in CRC tissues, and VPS53 expression was also determined in CRC cells. The changes of proliferation, migration, invasion, apoptosis, and autophagy of CRC cells were examined by a succession of functional experiments including CCK-8, flow cytometry, transwell assay, and electron microscopy. The levels of autophagy related proteins were evaluated by Western blotting analysis.

Results: RT-qPCR results found that VPS53 was downregulated in CRC tissues and cells, and Beclin 1 expression was also decreased in CRC tissues. There was a positive correlation between VPS53 and Beclin 1. Functional results showed that overexpression of VPS53 could suppress proliferation, migration, and invasion, and accelerate apoptosis and autophagy of CRC cells. Also, VPS53 could upregulate Beclin 1 and LC3BII, suggesting the inductive effect of VPS53 on CRC cell autophagy. Furthermore, it was found that the autophagy inhibitor (Inhb) could attenuate the inhibition of VPS53 on CRC progression.

Conclusion: VPS53 repressed CRC progression by regulating the autophagy signaling pathway, suggesting that VPS53 might be a promising therapeutic target for CRC.

Keywords: colorectal cancer, VPS53, autophagy, cell migration, cell invasion

Introduction

Colorectal cancer (CRC) is a malignant tumor transformed from the epithelial tissue of the colorectal mucosa under the comprehensive actions of various pathogenic factors such as genes, diet, and the environment.^{1,2} Its incidence and mortality are the third and fourth, respectively, among malignant tumors in the world.³ In developed countries, the incidence of CRC ranks second in malignant tumors.⁴ At present, the treatment of CRC is mainly comprehensive surgical treatment, including surgical resection of tumor tissues, chemotherapy, radiotherapy, biological therapy, and immunotherapy.^{5,6} However, the 5-year survival rate of CRC is not high due to its complex etiology, high malignancy, rapid tumor growth, and strong invasive ability.⁷

Vesicular transport mainly consists of budding, directional transport, tethering, anchoring, and membrane fusion.⁸ The initial connection between the transport

vesicle and membrane receptor is mediated by tethering factors, which recognize the transport vesicle and narrowed the distance between it and the membrane receptor.⁹ Vps53 might be involved in intracellular cholesterol transport and lysosomal sphingolipid homeostasis.¹⁰ Also, Vps53 was found to be differentially expressed in a variety of tumors.^{11–14} Specially, Gan et al found that VPS53 serves as a tumor suppressor in CRC, by inhibiting cell proliferation, attenuating tumor growth.¹⁵ However, the mechanism of VPS53 in CRC was still unclear.

In this study, we further confirmed expression of Vps53 and the regulatory relationship between Vps53 and the autophagy pathway in CRC. Functionally, we also determined the influence of Vps53 on CRC cell proliferation, migration, invasion, apoptosis, and autophagy by mediating the autophagy pathway. Therefore, we speculated that Vps53 might be of great clinical significance for the early diagnosis and treatment of CRC.

Materials and Methods

Patient Tissue Samples

CRC and adjacent normal tissues were collected from 15 patients with CRC who underwent surgical resection in Nanchong Central Hospital between November 2017 and February 2018. No patient had received chemotherapy before the operation. Written informed consent was obtained from each participant. Our study was also approved by the ethics committee of The Second clinical Medical College. Samples were placed in cryopreservation tubes, quick-frozen with liquid nitrogen, and transferred to a -80°C refrigerator.

Cell Culture

Normal colon FHC cells (BNCC338003) and LoVo (BNCC338601) cells were obtained from BeNa Culture Collection (Suzhou, China). SW620 (CCL-227), HT29 (HTB-38), SW480 (CCL-228), and HCT116 (CCL-247) cells were purchased from ATCC. FHC and HCT116 cells were maintained in RPMI-1640 medium (ATCC, cat. no. 30–2001) with 10% fetal bovine serum (FBS; Invitrogen Cat. no. 10,099–141) and glutamine. SW620 and SW480 cells were cultured in L-15 medium (Gibco, cat. no. 41,300,039) with 10% FBS, HT29 cells were grown in McCoy's 5A (Sigma, cat. no. M4892) with 10% FBS, and LoVo cells were maintained in F-12K medium (Gibco)

with 10% FBS. All cells were cultured at 37°C with 5% CO_2 .

Vector Construction and Transduction

PrimerSTAR Max DNA Polymerase Mix (Takara, Japan) was used to amplify the full-length VPS53, and the products were cloned into the pcDNA3.1+vector (Invitrogen). SW620 and LoVo cells (2×10^5 cells/well) were spread onto 6 well plates and incubated at 37°C for 8 hrs. After incubation, cells in each well were transfected with empty vector (NC) and pcDNA-VPS53 using Lipofectamine 3000 (Invitrogen) according to the instruction provided by the supplier. SW620 and LoVo cells were also treated with an autophagy inhibitor (Inhb).

RNA Extraction and Quantitative Real-Time PCR (RT-qPCR) Assay

Total RNA was extracted using TRIzol reagent (Invitrogen) from the tissue homogenates and cells. RNA was used to synthesize cDNA according to the instructions of the reverse transcription kit (Takara, Japan). Expressions of the target genes and housekeeping gene (GAPDH) were examined using the SYBR-Green PCR kit (Qiagen, Hilden, Germany) on the ABI 7500 Fast Real-Time PCR system. Relative expression levels of the target genes were analyzed using the $2^{-\Delta\Delta\text{Ct}}$ calculation method.¹⁶ All primers used in this experiment are listed in Table 1.

Western Blot Assay

The tissues were ground and 500 μL of RIPA lysate (Beyotime, cat. no. P0013B) was added to the processed cells in order to extract the total proteins. The Pierce BCA Protein Assay kit (Thermo Fisher Scientific) was used to quantify the concentrations of the extracted proteins. Thirty microgram protein was added into each of the holes in 10% SDS-PAGE, and the different sizes of proteins were separated by electrophoresis and transferred to PVDF membranes (Bio-Rad, cat. no.

Table 1 Primers Used in Realtime PCR in This Study

ID	Sequence (5'–3')	Length (bp)
GAPDH F	TGTTTCGTCATGGGTGTGAAC	154
GAPDH R	ATGGCATGGACTGTGGTCAT	
Beclin-1 F	AGGTTGAGAAAGGCGAGACA	133
Beclin-1 R	GTCCACTGCTCCTCAGAGTT	
VPS53 F	TGTTCCCAACCGAGCAATCTC	115
VPS53 R	ACGTTTCGTCTGACCTCTTACA	

Abbreviations: F, forward primer; R, reversed primer.

170–4157). After being sealed for 1h using 5% skim milk, the membranes were treated with primary antibodies at 4°C overnight. After treatment with secondary antibodies (Santa Cruz), the ECL system (Amersham Pharmacia Biotech) was used to colorize the membranes. The primary antibodies were: anti-GAPDH antibody (1:3000; Abcam, ab9485), anti-VPS53 antibody (0.4 µg/mL; Abcam, ab251759), anti-LC3B antibody (1:2000; Abcam, ab51520), and anti-Beclin 1 antibody (1.0 µg/mL; Abcam, ab62557).

Proliferation Assay

SW620 and LoVo cells (1×10^4 cells/well) were plated onto 96-well plates. After transfection with the VPS53-overexpressed plasmid or/and treatment with the autophagy inhibitor (Inhb), 3-MA for 0, 24, 48, and 72 hrs, 15 µL CCK-8 reagent was added to each well. After incubation for 3 hrs, the OD values were measured using a microplate reader (Thermo Fisher) at 450 nm.

Flow Cytometry Analysis

The treated SW620 and LoVo cells were harvested by cell dissociation and centrifuged ($1000 \times g$ for 5 mins). Cell deposits were suspended using PBS buffer. Apoptosis was assessed using the Annexin V-FITC/PI apoptosis detection kit (cat. no. MA0220). Following the instructions, 500 µL binding buffer, 5 µL Annexin V-FITC, and 10 µL PI were added to the cells for 10 mins. The number of apoptotic cells was monitored using flow cytometry (BD Biosciences).

Transwell Assay

Cell migration and invasion were examined by utilizing Transwell chambers (Costar, cat. no. 3422) with and without Matrigel matrix (Cat. no. 356,230). Two hundred microliters of treated SW620 and LoVo cells (1×10^5 cells/mL) in serum-free medium were placed in the upper chamber, and the medium with 20% FBS was put in the lower chamber. After incubation at 37 °C for 24 hrs, the migrated and invaded cells were fixed for 10 mins, stained with 0.5% crystal violet (Cat. no. C3886) for 20 mins, and observed using a microscope.

Transmission Electron Microscope

The treated SW620 and LoVo cells were collected and centrifuged ($500 \times g$ for 5 mins). Cell deposits at 4°C had precooled 5% glutaraldehyde solution added for 5 mins. After suspension and centrifugation, cells were treated with 5% glutaraldehyde and 10% bovine serum albumin (BSA; cat. no. BP1605) for 4 hrs on ice. After washing,

cells were fixed with 8% potassium pyrophosphate and 1% osmium tetroxide. After dehydration with acetone, the cells were soaked in epoxy resin for 2 days. Sections were obtained using a Leica EM UC7 Ultramicrotome. The sections were stained with 2% uranyl acetate and observed using a transmission electron microscope.

Statistical Analysis

All the experiments were repeated three times, and the data were expressed as mean $\pm$ standard deviation (SD). All results were analyzed using SPSS 19.0 (IBM, Chicago, IL, USA). The statistical graphs were drawn using GraphPad Software (Version 5.0). The differences were evaluated using Student's t-tests. The correlation between Beclin 1 and VPS53 was analyzed by Pearson's correlation. $P < 0.05$ indicated that the difference was statistically significant.

Results

Decreased VPS53 Was Found to Be Positively Correlated with Beclin 1 in CRC

To investigate the relationship between autophagy and CRC, we first identified the level of the autophagy-related gene (Beclin 1) in CRC tissues. Analysis showed that Beclin 1 expression was dramatically reduced in CRC tissues with respect to adjacent normal tissues ($P < 0.01$, Figure 1A). Also, to determine the potential contribution of VPS53 in CRC, we focused on and examined the level of VPS53 in CRC. As indicated by Figure 1B and C, the level of VPS53 was lower in CRC tissues than in adjacent normal tissues ($P < 0.01$). In addition, the results showed that expression of Beclin 1 was positively correlated with that of VPS53 in CRC ($R^2 = 0.4719$, Figure 1D). Furthermore, VPS53 expression was confirmed by RT-qPCR assay in human CRC cells, and the results determined that the level of VPS53 showed a significant decline in CRC cells, especially LoVo cells, in relation to normal colon FHC cells, and SW620 and SW480 cells displayed moderate VPS53 expressions ($P < 0.01$, Figure 1E). Therefore, SW620 and LoVo were used in vitro experiments subsequently.

Overexpression of VPS53 Suppressed Proliferation, Migration, and Invasion, and Facilitated Apoptosis and Autophagy of CRC Cells

In order to further determine the probably function of VPS53 on the proliferation, migration, invasion,

Figure 1 Downregulated VPS53 was positively correlated with Beclin 1 in CRC. **(A)** RT-qPCR results of expression of Beclin 1 in adjacent normal tissues (n=15) and CRC tissues (n=15), ** $P < 0.01$. **(B)** The level of VPS53 as also examined by RT-qPCR analysis in adjacent normal tissues (n=15) and CRC tissues (n=15), ** $P < 0.01$. **(C)** Western blotting analysis of VPS53 in adjacent normal and CRC tissues. **(D)** The correlation analysis of Beclin 1 and VPS53 in CRC tissues ($R^2=0.4719$, $p=0.0047$). **(E)** The level of VPS53 as determined by RT-qPCR assay in normal colon FHC cells and human CRC cells (SW620, HT29, SW480, HCT116, and LoVo), ** $P < 0.01$.

apoptosis, and autophagy of CRC cells, we transfected SW620 and LoVo cells with the pcDNA-VPS53 plasmid. Western blotting analysis found that VPS53 expression was notably raised in SW620 and LoVo cells after transfection with pcDNA3.0-VPS53 relative to cells transfected with the pcDNA3.0 vector (NC), indicating that there was a significant transfection effect of VPS53 in SW620 and LoVo cells ($P < 0.001$, Figure 2A). We further detected the effect of VPS53 overexpression on proliferation of SW620 and LoVo cells. According to the CCK-8 assay, cell viability was significantly reduced in SW620 and LoVo cells transfected with the pcDNA-VPS53 plasmid versus cells with NC ($P < 0.001$, Figure

2B). A characteristic of cancer is its capacity to evade apoptosis. So, we next examined the influence of VPS53 on CRC cell apoptosis using flow cytometry. As exhibited in Figure 2C, overexpression of VPS53 significantly accelerated apoptosis in SW620 and LoVo cells ($P < 0.001$). Also, the roles of VPS53 on the migration and invasion of SW620 and LoVo cells were further confirmed. As indicated in Figure 2D and E, transwell assay determined that overexpression of VPS53 markedly inhibited the migration and invasion of SW620 and LoVo cells ($P < 0.01$). Moreover, the effects of VPS53 overexpression on expressions of autophagy-related proteins including Beclin 1 and LC3B in SW620 and LoVo

Figure 2 Overexpression of VPS53 suppressed proliferation, migration, and invasion, and facilitated apoptosis and autophagy of CRC cells. SW620 and LoVo cells were transfected with the pcDNA-VPS53 plasmid and NC, respectively. **(A)** VPS53 expression was determined by Western blotting analysis and the VPS53 level was normalized to GAPDH, *** $P < 0.001$. **(B)** CCK-8 assay investigated the effects of VPS53 overexpression on SW620 and LoVo cells, ** $P < 0.01$. **(C)** Apoptotic analysis of SW620 and LoVo cells was evaluated by flow cytometry, and then the percentage of apoptosis was calculated, *** $P < 0.001$. **(D and E)** Transwell assays were used, and the results show the number of migrated and invaded cells per field, magnification, $\times 200$; ** $P < 0.01$. **(F)** Western blotting analysis displays expressions of Beclin 1 and LC3B, and the ratio of LC3BII/I and Beclin 1 level were counted based on the grayscale, * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$. **(G)** Electron microscopy shows the number of autophagosomes in each group. The red arrow denotes autophagosomes and the green arrow denotes the lysosomes.

cells were verified. Western blotting analysis showed that overexpression of VPS53 increased the protein expressions of Beclin 1 and LC3BII ($P < 0.001$,

Figure 2F). Simultaneously, it was observed that VPS53 could prominently increase autophagosomes in SW620 and LoVo cells (Figure 2G).

VPS53 Inhibited CRC Cell Carcinogenesis by Regulating Autophagy

The downstream regulation mechanism of VPS53 in CRC cells was further investigated. In order to confirm if the effect of VPS53 on the CRC process was achieved by regulating autophagy, the autophagy inhibitor (Inhb) was used to treat VPS53-overexpressed SW620 and LoVo cells, and functional experiments were performed. After a range of functional restoration assays, the results from

CCK-8 assay certified that overexpression of VPS53 dramatically suppressed CRC viability, while Inhb attenuated the suppression mediated by VPS53 in SW620 and LoVo cells ($P < 0.001$, Figure 3A). Flow cytometry assay also demonstrated that overexpression of VPS53 notably accelerated apoptosis of SW620 and LoVo cells, while Inhb weakened this acceleration induced by VPS53 ($P < 0.001$, Figure 3B). Also, it was found that Inhb treatment could reverse the inhibition of CRC cell migration and invasion

Figure 3 VPS53 inhibited CRC cell carcinogenesis by regulating autophagy. SW620 and LoVo cells were treated with the VPS53-overexpressed plasmid and the autophagy inhibitor (Inhb). (A) CCK-8 assay indicates the influence of Inhb on the VPS53-inhibited proliferation of SW620 and LoVo cells, $**P < 0.01$ vs NC group; $^{\#}P < 0.05$, $^{###}P < 0.001$ vs VPS53 group. (B) The role of Inhb on the VPS53-induced apoptosis analyzed by flow cytometry, and the apoptosis percentage is shown, $**P < 0.01$, $^{***}P < 0.001$ vs NC group; $^{\#}P < 0.05$ vs VPS53 group. (C and D) VPS53 plasmid and Inhb-treated SW620 and LoVo cells were subjected to the migration and invasion assays, and the migrated and invaded cells were counted, $**P < 0.01$, $^{***}P < 0.001$ vs NC group; $^{\#}P < 0.05$, $^{###}P < 0.001$ vs VPS53 group. (E) Western blot analysis results show expressions of LC3B and Beclin 1, and the quantitative results were analyzed, $**P < 0.01$, $^{***}P < 0.001$ vs NC group; $^{\#}P < 0.05$, $^{###}P < 0.001$ vs VPS53 group. (F) Ultrastructure of autophagic bodies observed by an electron microscope. The red arrow denotes autophagosomes and the green arrow denotes the lysosomes.

mediated by VPS53 overexpression ($P<0.05$, $P<0.01$, $P<0.001$, Figure 3C and D). More importantly, it was determined that expressions of LC3BII, Beclin 1, and VPS53 were markedly increased in VPS53-overexpressed SW620 and LoVo cells, whereas they were attenuated by Inhb treatment ($P<0.05$, $P<0.01$, $P<0.001$, Figure 3E). As shown in Figure 3F, autophagosome was enhanced in SW620 and LoVo cell by VPS53 overexpression, while reversed by Inhb treatment (Figure 3F). Collectively, these data showed that VPS53 inhibited proliferation, migration, and invasion, and induced apoptosis and autophagy by directly regulating autophagy pathways.

Discussion

The pathogenesis of CRC has not been fully elucidated. GARP can facilitate retrograde transport vector fusion into TGN, and loss of the GARP function can impair the growth, reproduction or viability of defective organisms.¹⁷ VPS53 as a subunit of GARP complexes, can participate in the reverse transport of proteins from endosomes to late golgi apparatus, and transport and accelerate the differentiation of pluripotent cells.¹⁷ Moreover, a large number of studies confirmed that VPS53 is downregulated in multiple cancers, such as medullary thyroid cancer,¹¹ prostate cancer,^{12,18} and cervical cancer.¹³ Also, VPS53 can induce apoptosis of ectopic endometrial stromal cells.^{14,14} More importantly, several studies disclosed that VPS53 was screened for low expression in CRC,^{19–21} and HCCS1, as a homologous gene of VPS53, has a strong anti-tumor effect on human colon cancer and liver cancer cells.¹⁵ In our study, we demonstrated that VPS53 was down-expressed in CRC tissues and cells relative to normal adjacent tissues or normal colon cells.

Autophagy, as highly-conserved lysosome-dependent auto-degradation pathways, has significant effect in maintaining cell homeostasis.^{22,23} Numerous studies also certified that autophagy can make a significant contribution in cancer,^{24,25} cardiovascular disease,²⁶ and neurodegenerative diseases by removing the damaged organelles and misfolded proteins.²⁷ In addition, more and more evidences showed that autophagy is vital to the development and treatment of CRC, and is also correlated with its prognosis.^{28,29} In autophagy, LC3 is processed into cytoplasmic LC3-I, and subsequently modified into membrane-bound LC3-II, which can be bound to an autophagosome membrane, and become a vital symbol of autophagosomes.³⁰ Autophagy levels can be evaluated by the LC3-II/LC3-I ratio.³¹ Microtubule-associated protein 1 light chain 3B (LC3B), as a homologue of yeast ATG8, is a crucial autophagy marker in mammals.³² Beclin-1 is

essential for the initial steps of autophagy, which indirectly implicates its important role in numerous biological cellular processes, including aging and cell death.³³ Autophagy induction can facilitate CRC cell death, while autophagy inhibition can accelerate CRC cell survival.³⁴ Therefore, autophagy-related pathways might be potential new targets for prevention and treatment of CRC. mTORC1-mediated autophagy can affect receptor tyrosine kinase phosphorylation in CRC by the mTORC2-regulated mechanism.³⁵ Stimulation of tumor-associated macrophage (TAM) autophagy can enhance the radio-sensitivity of CRC.³⁶ Besides, in this study, the expression of Beclin 1 was upregulated with increasing of LC3B II and cell apoptosis. This might be due to the interaction between Beclin 2 and Bcl-2. The combination of Bcl-2 and Beclin 1 can mediate cell survival and autophagy.³⁷ In our preliminary experiment, we found that Beclin-1 was lowly expressed in CRC tissues, and its expression was positively correlated with VPS53. We also found that VPS53 could markedly improve the LC3-II/LC3-I ratio and upregulate Beclin 1 in CRC. Moreover, functional experiments showed that the autophagy inhibitor (Inhb) could attenuate the inhibition of proliferation, migration, and invasion, and the promotion effects of apoptosis and autophagy in CRC. Therefore, it was demonstrated that VPS53 can suppress tumorigenesis and progression of CRC by regulating autophagy pathways.

Conclusions

It was determined that VPS53 is a critical regulator of CRC progression. VPS53 expression is prominently reduced in CRC, and overexpression of VPS53 can suppress the proliferation, migration, and invasion, and accelerate apoptosis and autophagy of CRC cells through induction of autophagy pathways. Therefore, our results suggested that VPS53 has a significant role in the developmental process of CRC.

Funding

This work was supported by North Sichuan Medical College City school cooperation program (18SXHZ0364, 18SXHZ0408, 19SXHZ0297); Science and Technology Research Project of Sichuan Province (2017JY0116); School Grade Research Key Project of North Sichuan Medical College (CBY18-A-ZD13), and Basic Scientific and Technological Strategic Cooperation of Nanchong Municipal Schools (NSMC20170311).

Disclosure

The authors declared no conflicts of interest.

References

1. Saltz LB. Colorectal cancer. *Hematol Oncol Clin North America*. 2015;29:ix. doi:10.1016/j.hoc.2014.10.012
2. Dulai PS, Sandborn WJ, Gupta S. Colorectal cancer and dysplasia in inflammatory bowel disease: a review of disease epidemiology, pathophysiology, and management. *Cancer Prevent Res*. 2016;9:887–894. doi:10.1158/1940-6207.CAPR-16-0124
3. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. *Gut*. 2017;66:683–691. doi:10.1136/gutjnl-2015-310912
4. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin*. 2015;65:87–108. doi:10.3322/caac.21262
5. Roncucci L, Mariani F. Prevention of colorectal cancer: how many tools do we have in our basket? *Eur J Internal Med*. 2015;26:752–756. doi:10.1016/j.ejim.2015.08.019
6. Svestka T, Krechler T. [Preventing colorectal cancer]. *Casopis Lekarů Ceskych*. 2016;155:27–29.
7. Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. *CA Cancer J Clin*. 2017;67:177–193. doi:10.3322/caac.21395
8. Best JT, Xu P, Graham TR. Phospholipid flippases in membrane remodeling and transport carrier biogenesis. *Curr Opin Cell Biol*. 2019;59:8–15. doi:10.1016/j.ccb.2019.02.004
9. Kummel D, Heinemann U. Diversity in structure and function of tethering complexes: evidence for different mechanisms in vesicular transport regulation. *Curr Protein Pept Sci*. 2008;9:197–209. doi:10.2174/138920308783955252
10. Hausman-Kedem M, Ben-Shachar S, Menascu S, Geva K, Sagie L, Fattal-Valevski A. VPS53 gene is associated with a new phenotype of complicated hereditary spastic paraparesis. *Neurogenetics*. 2019;19.
11. Shi L, Zhao SM, Luo Y, et al. MiR-375: A prospective regulator in medullary thyroid cancer based on microarray data and bioinformatics analyses. *Pathol Res Pract*. 2017;213:1344–1354. doi:10.1016/j.prp.2017.09.024
12. Rebbeck TR. Prostate cancer genetics: variation by race, ethnicity, and geography. *Semin Radiat Oncol*. 2017;27:3–10. doi:10.1016/j.semradi.2016.08.002
13. Kim TE, Kim YW, Hwang SY, et al. Candidate tumor suppressor, HCCS-1, is downregulated in human cancers and induces apoptosis in cervical cancer. *Int J Cancer*. 2002;97:780–786. doi:10.1002/ijc.10124
14. Zhang W, Zhang X, Zheng Y, et al. Preparation of polyaniline@MoS₂@Fe₃O₄ nanowires with a wide band and small thickness toward enhancement in microwave absorption. *ACS Appl Nano Mater*. 2018;1:5865–5875. doi:10.1021/acsanm.8b01452
15. Gan Y, Gu J, Cai X, Hu J, Liu XY, Zhao X. Adenovirus-mediated HCCS1 overexpression elicits a potent antitumor efficacy on human colorectal cancer and hepatoma cells both in vitro and in vivo. *Cancer Gene Ther*. 2008;15:808–816. doi:10.1038/cgt.2008.52
16. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2⁻(Delta Delta C(T)) method. *Methods*. 2001;25:402–408. doi:10.1006/meth.2001.1262
17. Vasan N, Hutagalung A, Novick P, Reinisch KM. Structure of a C-terminal fragment of its Vps53 subunit suggests similarity of Golgi-associated retrograde protein (GARP) complex to a family of tethering complexes. *Proc Nat Acad Sci USA*. 2010;107:14176–14181.
18. Goh CL, Eeles RA. Germline genetic variants associated with prostate cancer and potential relevance to clinical practice. 2014. *Prostate Cancer Prev*. 9–26. City; Springer.
19. Qi L, Ding Y. Screening of tumor suppressor genes in metastatic colorectal cancer. *Bio Med Res Int*. 2017;2017:1–7. doi:10.1155/2017/2769140
20. Nakao M, Kawauchi S, Uchiyama T, et al. DNA copy number aberrations associated with the clinicopathological features of colorectal cancers: identification of genomic biomarkers by array-based comparative genomic hybridization. *Oncol Rep*. 2011;25:1603–1611. doi:10.3892/or.2011.1246
21. Li H, Yang X, Wang G, et al. KDM4B plays an important role in mitochondrial apoptosis by upregulating HAX1 expression in colorectal cancer. *Oncotarget*. 2016;7:57866.
22. Smith M, Wilkinson S. ER homeostasis and autophagy. *Essays Biochem*. 2017;61:625–635. doi:10.1042/EBC20170092
23. Yan Y, Finkel T. Autophagy as a regulator of cardiovascular redox homeostasis. *Free Radic Biol Med*. 2016;109:108–113. doi:10.1016/j.freeradbiomed.2016.12.003
24. Chen C, Lu L, Yan S, et al. Autophagy and doxorubicin resistance in cancer. *Anti-Cancer Drugs*. 2018;29:1–9. doi:10.1097/CAD.0000000000000572
25. Amaravadi R, Kimmelman AC, White E. Recent insights into the function of autophagy in cancer. *Genes Dev*. 2016;30:1913–1930. doi:10.1101/gad.287524.116
26. Bravo-San Pedro JM, Kroemer G, Galluzzi L. Autophagy and mitochondria in cardiovascular disease. *Circ Res*. 2017;120:1812–1824. doi:10.1161/CIRCRESAHA.117.311082
27. Guo F, Liu X, Cai H, Le W. Autophagy in neurodegenerative diseases: pathogenesis and therapy. *Brain Pathol*. 2018;28:3–13. doi:10.1111/bpa.12545
28. Yu T, Guo F, Yu Y, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. *Cell*. 2017;170:548–563.e516. doi:10.1016/j.cell.2017.07.008
29. Mokarram P, Albokashy M, Zarghooni M, et al. New frontiers in the treatment of colorectal cancer: autophagy and the unfolded protein response as promising targets. *Autophagy*. 2017;13:781–819. doi:10.1080/15548627.2017.1290751
30. Dikic I, Elazar Z. Mechanism and medical implications of mammalian autophagy. *Nat Rev Mol Cell Biol*. 2018;19:349. doi:10.1038/s41580-018-0003-4
31. Aparicio I, Munoz PM, Salido G, Pena F, Tapia J. The autophagy-related protein LC3 is processed in stallion spermatozoa during short- and long-term storage and the related stressful conditions. *Animal*. 2016;10:1182–1191. doi:10.1017/S1751731116000240
32. Xu WN, Chen DH, Liu WB, Xu JX, Yang SS. Molecular characterization of microtubule-associated protein 1-light chain 3B in megaloblastemia amblycephala fed with high fat/berberine diets. *J Appl Gene*. 2018;59:345–355. doi:10.1007/s13353-018-0451-8
33. QJ W, Z Y. The Beclin 1-VPS34 complex—at the crossroads of autophagy and beyond. A Funderburk SF. *Trends Cell Biol*. 2010;20:355–362. doi:10.1016/j.tcb.2010.03.002
34. Liu L, Wang HJ, Meng T, et al. lncRNA GAS5 inhibits cell migration and invasion and promotes autophagy by targeting miR-222-3p via the GAS5/PTEN-signaling pathway in CRC. *Mol Therapy Nucleic Acids*. 2019;17:644–656. doi:10.1016/j.omtn.2019.06.009
35. Lampada A, O'Prey J, Szabadkai G, Ryan KM, Hochhauser D, Salomoni P. mTORC1-independent autophagy regulates receptor tyrosine kinase phosphorylation in colorectal cancer cells via an mTORC2-mediated mechanism. *Cell Death Differ*. 2017;24:1045–1062. doi:10.1038/cdd.2017.41
36. Shao LN, Zhu BS, Xing CG, Yang XD, Young W, Cao JP. Effects of autophagy regulation of tumor-associated macrophages on radiosensitivity of colorectal cancer cells. *Mol Med Rep*. 2016;13:2661–2670. doi:10.3892/mmr.2016.4820
37. Fu LL, Cheng Y, Liu B. Beclin-1: autophagic regulator and therapeutic target in cancer. *Int J Biochem Cell Biol*. 2013;45:921–924. doi:10.1016/j.biocel.2013.02.007

OncoTargets and Therapy

Dovepress

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>